Using AI to
detect cancer

Seeing What Humans Cannot

By decoding cell-free biomarker patterns of once unthinkable complexity, Freenome’s medical artificial intelligence (AI) platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies.


How AI genomics works

By training on thousands of cancer-positive blood samples, our AI genomics platform learns which biomarker patterns signify a cancer’s stage, type, and most effective treatment pathways.

Training on healthy samples helps us establish what a normal composition of cell-free biomarkers should look like, and provides a reference set to study other age-related conditions.


What we detect

When tumor activity destroys immune cells and other
healthy tissues, fragments of DNA and RNA continue to
circulate, cell-free, before being reabsorbed. Other cell-free 
nucleic acids are shed directly by the tumor itself.

Taken together, cell-free (cf) biomarkers, which also include 
circulating proteins, provide a real-time snapshot of cancer’s 
activity in the body, with revolutionary implications for screening and treatment.


Copy of comp bio@2x (1).jpg

Mapping the cell-free (cf) genome



Provides insights into immune response and tumor heterogeneity.


Records which genes were actively expressed at time of apoptosis.


Identifies proteins associated with specific tumor types.


Detecting beyond the tumor

Freenome’s medical AI genomics allows it to process all of the cfDNA in the blood—60-80% of which is thought to come from immune cells—giving clinicians a clearer picture of early-stage cancer and generating powerful therapeutic insights.